Drug Res (Stuttg) 2015; 65(10): 532-534
DOI: 10.1055/s-0034-1390419
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes

M. Kusunoki
1   Department of Internal Medicine, Medical Clinic, Aichi Medical University, Nagoya, Japan
,
D. Sato
2   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
T. Nakamura
2   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
Y. Oshida
3   Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan
,
H. Tsutsui
4   Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan
,
Y. Natsume
5   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
K. Tsutsumi
6   Okinaka Memorial Institute for Medical Research, Tokyo, Japan
,
T. Miyata
7   Vascular Center, Sanno Medical Center, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

received 30 July 2014

accepted 05 September 2014

Publication Date:
04 November 2014 (online)

Zoom Image

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to improve the glycemic control and blood hemoglobin A1c (HbA1c) concentrations. However, there are few reports as yet suggesting that DPP-4 inhibitors may also improve insulin resistance and the serum lipid profile in the clinical setting. This study was aimed at investigating the effect of 14-week treatment with teneligliptin (20 mg/day) on the homeostasis model assessment ratio (HOMA-R), an indicator of insulin resistance, and serum lipid profile in 9 patients with type 2 diabetes. The treatment produced a significant decrease of the blood glucose and HbA1c concentration (blood glucose: p=0.008; HbA1c: p=0.038), and also improved HOMA-R (p=0.039). Furthermore, the patients showed elevation of the serum HDL-cholesterol level (p=0.032), and a tendency towards reduction of the serum triglyceride level. The results indicate that teneligliptin acts not only to improve the blood glucose control, but also to improve the insulin resistance and serum lipid profile in Japanese type 2 diabetes patients.